Vimta Labs Limited has informed the Exchange about Investor Presentation
1
INVESTOR PRESENTATION
Q2 & H1 FY26
2 2
Disclaimer
The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.
This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.
No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.
3
Table Of Contents
• Q2 & H1 FY26 Earnings
• Company Overview
•
Industry Landscape
• Our Competitive Advantage
• Way Forward
4
Section 01
Q2 & H1 FY26 Earnings • Q2 & H1 FY26 Highlights
•
Key Metrics: Q2 & H1 FY26
• Profit & Loss Statement
•
•
Financial Track Record
Shareholding Pattern
5 5
Q2 FY26 Highlights
Rs 1,045 Mn
Total Income
Rs 4.5
EPS
Rs 369 Mn Margin 35.3%
EBITDA
Rs 478 Mn
CAPEX (Cash Outflow)
Rs 263 Mn
PBT
Rs 199 Mn Margin 19.1%
PAT
6
H1 FY26 Highlights
Rs 2,038 Mn
Total Income
Rs 8.7
EPS
Rs 723 Mn Margin 35.5%
EBITDA
Rs 545 Mn
Cash & Cash Equivalent*
Rs 515 Mn
PBT
Rs 388 Mn Margin 19.0%
PAT
*Cash and Cash equivalents includes other bank balances
7
Key Metrics: Q2 FY26
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
PAT
PAT Margin
22.3% YoY
20.6% YoY
17.1% YoY
19.9%
19.0%
35.8%
35.7%
35.3%
19.1%
854
993
1045
306
354
369
170
189
199
5
0
3.8
4.3
4.5
Q2FY25
Q1FY26
Q2FY26
Q2FY25 Q1FY26 Q2FY26
Q2FY25 Q1FY26 Q2FY26
Q2FY25 Q1FY26 Q2FY26
8
Key Metrics: H1 FY26
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
PAT
PAT Margin
26.6% YoY
26.4% YoY
25.5% YoY
35.5%
35.5%
1,610
2,038
572
723
309
388
19.2%
19.0%
40%
35%
30%
25%
20%
15%
10%
7.0
8.7
H1FY25
H1FY26
H1FY25
H1FY26
H1FY25
H1FY26
H1FY25*
H1FY26
*H1 FY25 EPS Adjusted due to issue of Bonus shares
9
Profit & Loss Statement
Particulars (₹ Mn)
Revenue from Operations
Other Income
Total Income
Material and Testing Costs
Cost of lab setup
Changes in inventories of work-in-progress
Employee benefits expense
Other expenses
Total Expenses
EBIDTA
EBIDTA (%)
Finance costs
Depreciation expense
Profit before tax
PBT (%)
Tax
Profit for the year
PAT (%)
Basic EPS (INR)
Q2 FY26
Q1 FY26
QoQ(%)
Q2 FY25
YoY (%)
H1 FY26
H1 FY25
YoY (%)
1,018
27
1,045
201
0
-
286
189
676
369
976
17
993
188
0
-
278
172
639
354
35.3%
35.7%
4
102
263
3
99
253
25.1%
25.4%
64
199
19.1%
4.5
64
189
19.0%
5.2%
4.1%
4.0%
5.4%
847
7
854
182
2
-
239
126
548
306
35.8%
4
83
219
25.6%
49
170
19.9%
22.3%
20.6%
20.0%
17.1%
4.3
5.2%
3.8
16.4%
1,994
44
2,038
389
0
-
564
361
1,315
723
35.5%
7
201
515
1,596
14
1,610
325
2
-
464
248
1,038
572
35.5%
9
163
401
25.3%
24.9%
127
388
19.0%
8.7
91
309
19.2%
7.0
26.6%
26.4%
28.7%
25.5%
25.0%
10
Financial Track Record
TOTAL INCOME (₹ Mn)
PROFITABILITY (₹ Mn)
1,837 2,115 2,797 3,216 2,923 3,482 2,038
11.2% CAGR
18% 330
EBITDA & EBITDA Margin
29% 31% 33%
25%
PAT & PAT Margin
36%
36%
25.1% CAGR
4%
10%
15% 15%
19%
17% 19%
46.3% CAGR
538
817
984
977
1,262 723
214 413 482 488 668 388
68
FY20
FY21
FY22
FY23
FY24
FY25 H1FY26
FY20
FY21
FY22
FY23
FY24
FY25 H1FY26
FY20
FY21
FY22
FY23
FY24
FY25 H1FY26
Total Revenue
EBIDTA
EBIDTA Margin
PAT
PAT Margin
BALANCE SHEET RATIOS
RoE (%)
RoCE (%)
Debt to Equity
Total Capex
4% 11% 18% 17% 15% 18% 9%
15% 18% 25% 22% 19% 23% 16%
0.16 0.16 0.08 0.05 0.06 0.02 0.02
166 357 450 492 763 791 478
FY20
FY21
FY22
FY23
FY24 FY25 H1FY26
FY20 FY21
FY22 FY23 FY24 FY25 H1FY26
FY20 FY21
FY22 FY23 FY24 FY25 H1FY26
FY20 FY21
FY22 FY23 FY24 FY25 H1FY26
1. Financial numbers for the period FY24 & FY25 are from continuing operations and exclude Diagnostic and Pathological services business 2. CAGR for the period FY20-FY25
11
Shareholding Pattern
Shareholding as on 30th September 2025
Share Information as on 30th September 2025
Others 58.8%
Promoters 36.0%
DII 0.9%
FII 4.3%
NSE Ticker
BSE Ticker
Market Cap (INR Cr)
% free-float
Free-float market cap (INR Cr)
Total Debt (INR Mn)
Cash & Cash Equivalents (INR Mn)
VIMTALABS
524394
3,145.92
64.01%
2,013.58
67.97
545.38
Shares Outstanding
4,45,40,820
3M ADTV (Shares)*
41,19,851.88
3M ADTV (INR Cr)*
Industry
286.49
TIC
Source: NSE & BSE
#Cash and Cash equivalents includes other bank balances
12
Section 02
Company Overview
•
Vimta at a Glance
• Our Journey
• Our Offerings
• Geographical Presence
• Management
13 13
Vimta at a Glance
Established in 1984, VIMTA is one of India’s most renowned companies for contract research and
testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable
services and vast experience. The company’s broad capabilities span across biologics, small molecules,
agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, and
environment testing.
41+ Years Of experience in CRTO industry
1,300+ Dedicated Multi- Disciplinary Team
600,000+ Sq. Ft. of Ultra- modern lab spaces
10 Labs and Offices across India
~100 Successful Regulatory Audits
14
Our Journey
Infrastructure
People
Investment
Capabilities
Revenues
2024
600,000+ ft2
1300+
492 M
Pharma & Biopharma: Discovery & development services; Food; Environment; Electronics Testing
3,216 M
2015
400,000+ ft2
1000+
580 M
Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment Testing
1,073 M
2006
200,000+ ft2
600+
992 M
Clinical Research; Environment; Analytical Testing – Food & Pharma
542 M
1992
50,000+ ft2
150+
85 M
Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research
16 M
1984
500 ft2
6
200,000
Minerals & ores; Metals; Rice bran oil testing
156,000
1. Investment & Revenues in INR 2. Investments depicted may have spread across more than the denoted year
15
Our offerings
Drug discovery and development services
Food & Agri Testing
Electronics & Electricals Testing
Environment Testing & Consultancy
16
1. Drug discovery and development services
Offerings
Pharma Analytical
Clinical Research
Preclinical Research
Industry
Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health
Pharmaceuticals, Biologics, Medical Device, Agrochemical, Speciality Chemicals
Accreditations & Regulatory Approvals
Services
DCA, USFDA, WHO, EMA, DRAs of Ukraine, Turkey
CDSCO, USFDA, WHO, MHRA, NPRA, and European DRAs
OECD-GLP, CCSEA, DSIR, AAALAC
Wide range of analytical services
• E&L studies • Stability testing • Method
development
• Validations • Genotoxic impurities
• Elemental analysis In vitro studies • • Physical
Characterisation
• Dissolution Testing
• Microbiology •
Immunogenicity studies
• Characterization • Bioassays
• BA/BE Studies
• Bioanalytical
• Clinical Trials (Phase I to
IV)
• Clinical End Point
Studies
• Claim Studies
• Comprehensive in vitro, ex vivo
and in vivo studies
• ADME, and PK •
IND enabling packages (genetic toxicology, safety pharmacology, general toxicology, & toxicokinetic studies).
• Chronic toxicology, reproductive toxicology, neurotoxicology, immunotoxicology, and carcinogenicity
• Biowaiver and alternative to
animal studies
• Ecotoxicology, environmental fate
and metabolism studies
17
17
2. Food & Agri Testing
Industry
Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed
No. of Locations
7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida)
Accreditations & Regulatory Approvals
• FSSAI, ISO 17025, BIS, APEDA, EIC, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board • Hyderabad Lab is a National Reference Lab for Water & Beverages Testing • Mumbai Lab is a National Food Laboratory, operated for FSSAI
Services
• Food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis for
all agri, food, food products, water and beverages
• New product development support, validations • Shelf-life assessments • Packaging material testing • Nutraceuticals testing, method validations • Animal feed analysis • Argo-chemical (crop sciences): support for research and development, method development, validation and
testing for regulatory submissions in India, Europe, South America, Japan, Southeast Asia
18
18
3. Electricals & Electronics Testing & Certification
Industry
Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries
No. of Locations
1 (Hyderabad)
Accreditations & Regulatory Approvals
ISO 17025, TEC
• • BIS & NABCB
Services
• EMI/EMC testing • Radio Frequency testing • Environmental & reliability testing • Mechanical & electrical safety testing • Performance testing • Product Certification • CE marking
19
19
4. Environment Testing & Consultancy Services
Industry
Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc.
No. of Locations
4 (Hyderabad, Chennai, Kolkata and Noida)
Accreditations & Regulatory Approvals
Services
• MoEF, ISO 17025, QCI/NABET, OSHAS 45000
• Post project monitoring • • Advanced testing & tailor-made services (CEMS validation, PG for pollution equipment, Dioxins, Furans,
Industrial hygiene & Indoor air
Industrial Gas, VOC as per LEED and EPA)
• Offshore monitoring • SIA & hydrogeological studies • EHS audits, Hazardous waste study, Life cycle assessment • Due diligence studies • Green audit, Metrological studies • Noise, air, traffic modelling etc.
20
20
Geographical Presence
Food
Environment
Hyderabad
Ahmedabad
Noida
Mumbai (NFL)
Nashik
Bengaluru
Nellore
Hyderabad
Chennai
Noida
Kolkata
Electrical and Electronics
Hyderabad
Hyderabad (Headquarters)
Food
Electronics & Electrical
Pharma
Environment
21
Key Management Team
S P Vasireddi Executive Chairman
Harita Vasireddi Managing Director
Sreenivas Neerukonda Executive Director
• Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.
• Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.
• Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.
• Her Core competencies include
management & driving organizational adaptability and development, quality management systems, and risk management.
•
She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India
•
Sreenivas’s core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal-oriented performance.
• He holds an MBA in
Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.
Harriman Vungal Executive Director - Operations
• Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.
• He has led the Company’s effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.
• He holds D. Tech in Electronics
from Toronto, Canada.
Siva Kambhampati Chief Financial Officer
•
Siva is a seasoned finance professional with a strong academic foundation. He is a CA and secured 63rd rank in cost accountancy. With over 16 years on experience in the engineering and pharmaceutical industries, he brings diverse expertise in strategic financial planning & management, product costing & pricing, and treasury management.
He has previously worked at Artson engineering Ltd. (A TATA Enterprise, Hyderabad as a CFO.
22
Section 03
Industry Landscape • Market Opportunity
•
Factors Driving Industry Growth
23 23
Markets Opportunity (Global)
Pharmaceutical Analytical Testing
Preclinical
Food Testing
Environment Testing
Electronics Testing
14,580
14,340
36,250
9,320
9,740
)
n M D S U
(
25,330
7,430
3,990
6,250
2,550
2025 | 2030
2024 | 2034
2025 | 2030
2025 | 2030
2023 | 2030
24
l
a b o G
l
Markets Opportunity (Indian)
Pharmaceutical Analytical Testing
Preclinical
Food Testing
Environment Testing
Electronics Testing
309
394
1,799
460
i
n a d n
I
)
n M D S U
(
185
211
832
293
100
50
2025 | 2030
2024 | 2030
2024 | 2033
2024 | 2030
2021 | 2028
25
Factors Driving Industry Growth
•
Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry
• Specialized knowledge, skills and
testing tools that CROs can provide
• Growing international food
regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third- party inspection & testing
Drug Discovery & Development
Electrical & Electronics Testing
• Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives
• Green push by Government for
electrical vehicles
Food Testing
Environment Testing
•
Increase in regulations to address the growing concerns of air, water and soil contamination
26
Section 04
Our Competitive Advantage
• Our Position in the CRTO Landscape
• Our Strength
27 27
Our Position in the CRTO Landscape
Pharma Analytical
Clinical Research
Electronics & Electricals
• #1 in India
• Among the most reputed CROs in
• One of the leading labs in
• Customers – 90% of India top 20
• 36% revenues from overseas
India
Southern India
• 75% of revenues from overseas
Food Testing
Preclinical
Environment
• #1 in India • Serving 7 of India’s top 10 food
companies
• The only private EU commission
approved lab in India
• Amongst Top 5 in India
• Among top 5 in India
• Customers – PSUs, large
corporations across industries
28
28
Our Strengths
Infrastructure
Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium
Innovations
Continuous addition of services and evolving excellence
Knowledge
Multi-disciplinary, knowledgeable, skilled and trained manpower
Customer Centricity
Compliance
Technology
Long term partnerships with customers
Strong culture of quality and compliance Long & successful regulatory track record – cGMP, GLP, GCP
Wide range of state-of- the-art technologies and scalable capacities
29
Section 05
Way Forward • Our Key Growth Drivers & Strategies
30 30
Our Key Growth Drivers & Strategies
Favourable markets
Core business strategies
Core operational strategies
Best practices
Growth momentum
Capacity expansions
Operational excellence
Good corporate governance
in markets
Growing demand
for safe & quality - drugs, food, diagnostics, electronics & clean environment
Service innovations
Hiring right talent
Risk management
Penetration into new markets
Quality & compliance culture
Listening to customers’ needs
Customer partnerships
Cutting edge technologies
Continuous learning
31
THANK YOU
Vimta Labs Ltd.
Siva Kambhampati | Chief Financial Officer
Siva.Kambhampati@vimta.com
Registered Office
#142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051
Ernst & Young
Siddesh Chawan
Advait Bhadekar
NSE: VIMTALABS
ISIN: INE579C01029
Siddesh.Chawan@in.ey.com
Advait.Bhadekar@in.ey.com
BSE: 524394
Website: www.vimta.com
32